All In Biotech

Drug Trial Radar · NCT07069712

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

A Master Protocol of an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jul 17, 2025

Primary completion

Nov 9, 2027

Study completion Jul 16, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Jul 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.

Conditions

  • Gastroesophageal Adenocarcinoma

Interventions

  • Sonesitatug VedotinDrug

    Sonesitatug Vedotin will be administered as an IV infusion.

  • RilvegostomigDrug

    Rilvegostomig will be administered as an IV infusion.

  • Trastuzumab Deruxtecan (T-DXd)Drug

    T-DXd will be administered as an IV infusion.

  • CapecitabineDrug

    Capecitabine (Fluoropyrimidine) will be administered orally as chemotherapy standard of care.

  • 5-Fluorouracil (5-FU)Drug

    5-FU (Fluoropyrimidine) will be administered as a continuous IV infusion as chemotherapy standard of care.

  • FLOT ChemotherapyDrug

    FLOT (5-FU, leucovorin, oxaliplatin, and docetaxel) Chemotherapy will be administered as an IV infusion.

  • Calcium folinateDrug

    Calcium folinate will be administered as an IV infusion as chemotherapy standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: Until sub-study completion, up to 38 months
  2. Percentage of participants with pathological complete response (pCR)Time frame: Until sub-study completion, up to 38 months

Locations

70 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Newark, Delaware · Recruiting

  • Research Site

    Washington D.C., District of Columbia · Recruiting

  • Research Site

    Fairway, Kansas · Recruiting

  • Research Site

    North Shores, Michigan · Recruiting

  • Research Site

    New York, New York · Withdrawn

  • Research Site

    New York, New York · Completed

  • Research Site

    Pittsburgh, Pennsylvania · Recruiting

  • Research Site

    Toronto, Ontario, Canada · Withdrawn

  • Research Site

    Montreal, Quebec, Canada · Recruiting

  • Research Site

    Montreal, Quebec, Canada · Recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Changchun, China · Recruiting

  • Research Site

    Changzhi, China · Recruiting

  • Research Site

    Chengdu, China · Recruiting

  • Research Site

    Chengdu, China · Recruiting

  • Research Site

    Fuzhou, China · Not yet recruiting

  • Research Site

    Hangzhou, China · Recruiting

  • Research Site

    Hangzhou, China · Recruiting

  • Research Site

    Kunming, China · Recruiting

  • Research Site

    Qingdao, China · Recruiting

  • Research Site

    Shanghai, China · Recruiting

  • Research Site

    Shijiazhuang, China · Withdrawn

  • Research Site

    Tbilisi, Georgia · Recruiting

  • Research Site

    Tbilisi, Georgia · Recruiting

  • Research Site

    Tbilisi, Georgia · Recruiting

  • Research Site

    Tbilisi, Georgia · Recruiting

  • Research Site

    Florence, Italy · Recruiting

  • Research Site

    Milan, Italy · Recruiting

  • Research Site

    Milan, Italy · Recruiting

  • Research Site

    Milan, Italy · Recruiting

  • Research Site

    Modena, Italy · Withdrawn

  • Research Site

    Pisa, Italy · Recruiting

  • Research Site

    Rozzano, Italy · Recruiting

  • Research Site

    Udine, Italy · Not yet recruiting

  • Research Site

    Vicenza, Italy · Recruiting

  • Research Site

    Chūōku, Japan · Recruiting

  • Research Site

    Fukuoka, Japan · Recruiting

  • Research Site

    Hidaka-shi, Japan · Recruiting

  • Research Site

    Kashiwa, Japan · Recruiting

  • Research Site

    Kitaadachi-gun, Japan · Recruiting

Showing 40 of 70 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.